Panelists

Bob Goodman – President & CEO of Phiar Corporation
Prior to his position at Phiar Corporation, Bob Goodman was CEO of a semiconductor device related company, Kentron Technologies from 2000 until 2004, and President and CEO of Luxtron Corporation, a West Coast based semiconductor equipment company, from 1995 until 2000. He has also held senior management positions at Texas Instruments and Wyse Technology, in addition to serving for 5 years as an officer in the U. S. Army prior to beginning his career in high technology. Mr. Goodman has over 25 years of experience in large, medium and "start-up" high technology related companies. His experience has included senior management and leadership expertise in very complex, highly competitive and quickly changing environments on a worldwide scale. He is very active with the semiconductor standards organization "JEDEC" and has served on the Board of Governors for the Electronics Industry Alliance (EIA). He has worked closely with leading semiconductor manufacturers, OEMs, and distributors in worldwide markets including the U.S., Europe, Japan, China, Taiwan and South Korea. He received his BS from the United States Military Academy and an MBA from Saint Edward's University.

Garret Moddel - Chairman & CTO of Phiar Corporation
In addition to his role at Phiar Corporation, Dr. Moddel is Professor of Electrical & Computer Engineering at the University of Colorado at Boulder. Previously he served as Manager of Materials and Devices for the Optoelectronic Computing Systems Center at UC-Boulder. He was was a founding employee of SERA Solar, a Silicon Valley start-up and has served as a consultant to other start-ups. In 2002, he was named the University of Colorado Inventor of the Year in the Physical Sciences. He received his M.S. & Ph.D. in Applied Physics from Harvard University and his B.S.E.E. from Stanford University, and he is a Fellow of Optical Society of America.

W. Thomas Cathey - Founder and Chief Technology Officer of CDM Optics
W. Thomas Cathey is a joint inventor of CDM Optics' Wavefront Coding technology. From 1997 to 2003, Dr. Cathey served as a Research Professor of Electrical and Computer Engineering at the University of Colorado, where he has held the title of Associate Professor and Professor of Electrical Engineering since 1968. Prior to working at the University, he was a Technical Advisor and Group Scientist at Rockwell International. From 1987 to 1993, he served as the Director for the National Science Foundation's Engineering Research Center for Optoelectronic Computing Systems at UC-Boulder. He has been a consultant to large and small companies in the areas of imaging systems, coherent imaging, laser systems, optical adaptive arrays, holographic interferometry, optical computing, tomography, millimeter wave generations, and electromagnetic compatibility. Dr. Cathey holds a Ph.D. in Electrical Engineering from Yale University.

Edward Dowski - Founder and President of CDM Optics
Edward Dowski is a joint inventor of CDM Optics' Wavefront Coding technology. Formerly a Research Associate at the University of Colorado, Dowski holds numerous patents and has won high-level awards for his work, including the 1995 Technology Transfer Society's University-to-Business Technology Transfer Award; the 1995 Colorado Advanced Technology Institute's Technology Transfer Award; and the 1994 OCS/Collins Family's Technology Transfer Award. From 1986-1988, he was the lead on-site Signal Processing Engineer at Raytheon Corporation, and in 1989 spent one year in Japan as a Research Fellow for the American Electronics Association. He graduated with a Ph.D. from the University of Colorado in Electrical Engineering in 1993.

Michael Holers - Co-Founder and Chief Scientific Officer of Taligen Therapeutics
In addition to his roles at Taligen Therapeutics, Dr. Holers holds faculty positions at the University of Colorado at Denver and Health Sciences Center where he is Head of the Rheumatology Division, Professor of Medicine and Immunology, and Smith Professor of Rheumatology. Prior to joining the UCDHSC faculty, he held appointments at the Washington University Medical School. Dr. Holers has done commercial consulting and is also a co-founder of Touch of Life Technologies (TolTech) in Denver, CO. He has trained over 25 students and written more than 120 peer-reviewed publications. Dr. Holers currently is an Advisory Committee Member and Chair for the Dean's Distinguished Seminar Series. Additionally, he holds numerous awards from the Arthritis Foundation in addition to many other honors including the American Rheumatism Association Senior Fellowship Award and the University of Colorado's 2004 Inventor of the Year in 2004 award. Dr Holers received his B.S. in Biology from Purdue University in 1974 and his M.D. from Washington University School of Medicine in 1978.

Woodruff Emlen - President of Taligen Therapeutics Dr. Emlen, MD, was in academic medicine at the University of Washington and the University of Colorado Health Sciences Center as Professor of Medicine (Rheumatology) and Immunology for nearly 20 years. His research focused on the pathogenesis of autoimmune disease; he has published more than 75 articles and abstracts and is holder/co-holder on 4 patents. In 1997 he left UCHSC to join Connetics Corporation in Palo Alto, Ca. as Vice President of Exploratory Medicine. Shortly thereafter, he became one of the founders of InterMune, a spin-out of Connetics, where he served as Vice President of Scientific Affairs from 1998-2002. InterMune received its initial venture funding in 1998 and went public in 2000. He returned to Colorado in 2002 to do consulting, and co-founded Taligen with his former colleague Dr. Michael Holers, in March of 2004. He is currently on the Clinical Faculty of UCHSC.

Panelists' Companies

Taligen Therapeutics, Inc. is a biotechnology company founded in March 2004 to develop and commercialize technology from the University of Colorado for the treatment of serious inflammatory diseases. Its innovative approach manipulates complement proteins of the immune system to inhibit inflammation and to target inhibitors of the inflammation to specific sites of tissue injury. By targeting the complement system, the technology inhibits inflammation proximal, or upstream, in the inflammatory cascade, such that blockade at a single step results in the down-regulation of multiple effector mechanisms. Taligen expects its products to be effective in multiple inflammatory diseases. Based on medical need, the competitive landscape, and pre-clinical data, Taligen currently focuses on three areas of major unmet medical need: asthma, traumatic brain injury, and autoimmune disease. Products are now in pre-clinical development, with estimated time to Phase I studies of two years. Taligen operates with grants and seed funding and is currently seeking additional seed investment.

CDM Optics, Inc. was founded in 1996 by W. T. Cathey, Edward Dowski, and R. C. Mercure, Jr. to commercialize the Wavefront Coding™ technology invented by Cathey and Dowski while at the University of Colorado at Boulder. An innovative combination of optical and electronic processing, WaveFront Coding ™ produces depth-of-field clarity not previously possible, while enabling smaller and lighter devices. The processing innovation corrects the distortions produced by inexpensive materials, allowing optical plastics to substitute for glass; and its digital-electronic corrections replace conventional complex electronics and machine solutions. The technology has multiple applications in consumer, medical, and scientific and defense products. CDM Optics has steadily achieved important development milestones, and in March of this year, announced its acquisition by OmniVision Technologies, Inc., one of the world's leading suppliers of CMOS image sensors. All of CDM's eighteen employees remain in Boulder with CDM, which now operate as a wholly owned subsidiary of OmniVision.

Phiar Corporation is an early stage company applying the concepts of metal-insulator nanotechnology to terahertz-wave and ultra-high-speed electronic components founded on basic research conducted at the University of Colorado at Boulder. The result is a breakthrough platform technology that lends itself to multiple applications, including high-speed computing and communications, and the emerging field of terahertz imaging. With investments from Menlo Ventures, Phiar has demonstrated basic devices and recently entered into a joint development agreement with Motorola.